At the news
? BULLISHIMPACT 7/10 6-K filed Jun 1, 2026 at 09:00 ET
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026. Median OS for second-line metastatic patients was 11.2 months vs historical ~4-6 months, with a favorable safety profile (no treatment-related deaths). The data de-risks the platform and supports advancement of the IMPACT trial.
- Pooled analysis of three Phase I/II studies in locally advanced or metastatic PDAC.
- Second-line metastatic mOS: 11.2 months from enrollment (historical ~4-6 months).
- Second-line locally advanced mOS: 11.1 months from enrollment (historical ~9 months).
- Third-line metastatic mOS: 7.9 months from enrollment (historical ~4-7 months).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access